NeuroSigma's leadership is made up of experts in business management and the healthcare industry. Together they provide extensive experience gained through years of creating and guiding successful companies and innovative medical research.
Leon Ekchian, Ph.D.
PRESIDENT AND CEO
Dr. Ekchian has served as a member of our board of directors and as our President and Chief Executive Officer since our founding in 2008. Prior to co-founding NeuroSigma in March 2008, Dr. Ekchian served from 2005 to 2006 as President of Arrowhead Research Corporation, a publicly-traded company that commercializes innovative nanotechnologies in the electronic and biotech industries. From 1996 to 2005, Dr. Ekchian served as President and Chief Executive Officer of Litex, Inc., a company focused on commercializing an advanced automotive emission-control technology. Dr. Ekchian was a business development executive at Lockheed Martin from 1993 to 1996, where he focused on forming new ventures and evaluating new business plans and licensing opportunities. From 1988 to 1993, Dr. Ekchian was a program manager at Litton Industries developing ground-based and airborne tracking systems.
Dr. Ekchian received a B.S., M.S. and Ph.D. in electrical engineering from the Massachusetts Institute of Technology and an M.B.A. from the Anderson School of Management at UCLA.
Ian A. Cook, M.D.
SENIOR VICE-PRESIDENT AND CHIEF MEDICAL OFFICER
Dr. Cook has been our Chief Medical Officer and Senior Vice President since January 2014, previously having served as a medical advisor to the Company since 2009. An inventor of trigeminal nerve stimulation, he brings a track record of innovation in the use of technology in the management of brain disorders as well as of translational research in treatment development. Formerly the Miller Professor of Psychiatry and of Bioengineering at UCLA, he received years of NIH and industry research support for work on biomarker and treatment development, and founded the rTMS Treatment Service at UCLA. Before joining the Company, he served as Chief of Staff at the UCLA Resnick Neuropsychiatric Hospital, Chair of the Faculty at the David Geffen School of Medicine at UCLA, member of the ACO Governing Board for UCLA Health, and a standing member of the NIH's ITVA Integrated Review Group.
Dr. Cook earned his BSE in Bioengineering / Electrical Engineering and Computer Science from Princeton University and his MD from Yale University. He completed his residency training and research fellowship at UCLA before joining the faculty in 1995. He holds ABPN board certification in Psychiatry, was elected a Distinguished Fellow of the American Psychiatric Association, and is a Fellow of the International College of Neuropsychopharmacology. He is an author of over 115 peer-reviewed original research articles and several dozen review articles, monographs, and book chapters.
Chief Financial Officer
Mr. Wild joined as NeuroSigma’s Chief Financial Officer in April 2015, after a career in public accounting and consulting. He started with the Auditor General of Arizona after college, then joined Ernst & Young in 1973 where he became an audit partner specializing in public company accounting and financial reporting. In 1991 he joined the regional accounting firm of Stonefield Josephson, Inc. (merged with Marcum LLP in 2010) where he started the public company practice, was partner in charge of accounting and auditing, and developed the firm’s assurance practice serving multi-national clients in the high technology, entertainment, biotechnology/medical technology, manufacturing and service industries. After Marcum, Mr. Wild became a consultant to medium sized businesses providing technical accounting and CFO services to medium sized businesses, advising on capital formation, as well as consulting to large publicly held companies needing guidance on complex accounting and SEC reporting issues.
Mr. Wild received a Bachelor of Science degree in accounting from Arizona State University, a Master of Science in Taxation from Golden Gate University, and completed the Executive Management program at the Kellogg School of Business at Northwestern University. He has been a frequent lecturer in accounting, financial and SEC reporting for the Center for Professional Education, Inc. and American Institute of Certified Public Accountants. Mr. Wild is licensed as a certified public accountant in California and Florida.
Colin P. Kealey, M.D
Vice President, Advanced Development and Medical Affairs
Dr. Kealey has served as our Director of Global Medical Affairs and Corporate Projects since March 2014. Dr. Kealey has been with NeuroSigma since September 2011, having previously served as our Manager of Business Development. In this role, Dr. Kealey spearheaded the introduction of eTNS to major epilepsy centers throughout the EU and Canada, and interfaced with key opinion leaders in the field to convey the science behind eTNS and how it may fit into their current clinical practice. Dr. Kealey also served as Co-Principal Investigator on two of our National Institutes of Health (NIH) grants. In addition, he assisted with the preparation of materials submitted to the FDA, which led to the approval of our IDE application, and has been a major contributor to the design of our planned pivotal trial of eTNS for epilepsy. Prior to joining NeuroSigma, Dr. Kealey was a resident physician in the UCLA Department of Surgery from 2007 to 2011. During his time at UCLA, Dr. Kealey was responsible for all aspects of the care of surgical patients, ranging from outpatient procedures to critically ill patients in the intensive care unit. From 2009 to 2011, Dr. Kealey also served as a Post-Doctoral Researcher at the UCLA Center for Advanced Surgical and Interventional Technology, where he performed pre-clinical research and development on novel medical devices.
Dr. Kealey earned his B.S. in Biochemistry and Molecular Biology from the University of Wisconsin – Madison and his M.D. from the University of Iowa Carver College of Medicine.
Charles W. Winckler
Vice President of Financial Planning
Mr. Winckler brings over 18 years of industry experience in venture backed technology companies. Prior to his current role at NeuroSigma, Mr. Winckler held the position of CFO, and he has recently held the position of CFO and/or Senior Financial Advisor at US Seismic Systems, Inc., PBS Biotech, Inc., DevZuz Holdings, Inc.; Greenplum, Inc.; Vativ Technologies, Inc.; Litex, Inc.; and Sabeus, Inc. In addition, Mr. Winckler has represented start-up companies in various mergers and acquisitions deals. Prior to his involvement with venture backed technology companies, Mr. Winckler was a manager with Ernst & Young LLP's financial advisory services practice. During his four years in the financial advisory services practice, he participated in a number of engagements in the manufacturing, high-tech and media/entertainment industries and gained significant exposure to issues regarding M&A due diligence, business valuation, bankruptcy proceedings, litigation support, as well as financial and operational matters. Before joining Ernst & Young LLP's Financial Advisory Services Group, he spent over two years in Ernst & Young's information, communications and entertainment audit practice where his clients ranged from start-up ventures to major public companies with SEC reporting requirements. Mr. Winckler also served as Co-Chairman of This Little Light, a support organization for the Plastic and Reconstructive Surgery division at Children's Hospital Los Angeles.
Mr. Winckler received his B.A. in business economics from the University of California at Santa Barbara in 1990, and his masters of accounting, with a concentration in consulting, from the University of Southern California in 1991.
Vice President of Finance and Operations
Mr. Oseas has served as our Vice President of Finance & Operations since April 2015. Prior to joining NeuroSigma, he provided financial advisory services to early stage and emerging companies. Mr. Oseas has served as a financial consultant to NeuroSigma since 2010. From 1999 to 2004, Mr. Oseas was a senior manager with Ernst & Young LLP in their Transaction Advisory Services practice where he advised on buy-side and sell-side mergers and acquisitions transactions for both strategic and financial investors. Prior to that, Mr. Oseas was Director of Accounting and Assistant Controller at The Carsey-Werner Company from 1995 to 1999. Mr. Oseas started his career with Ernst & Young LLP serving in their audit and restructuring and reorganization practices from 1990 to 1995.
Mr. Oseas received a Bachelor of Arts degree in Economics and Psychology from The University of California, Los Angeles and is an active Certified Public Accountant.
A. David Johnson, Ph.D
Director of Advanced Materials
Dr. David Johnson has served as NeuroSigma’s Director of Advanced Materials since 2012. In this role he has led NeuroSigma’s Thin Film Nitnol fabrication and development efforts. Prior to joining NeuroSigma he founded the TiNi Alloy Company where he developed many of the tools and techniques for fabricating thin film nitinol. Dr. Johnson has had a distinguished career as an entrepreneur commercializing multiple thin film nitinol and other shape memory alloy technologies.
Dr. Johnson has a BS in physics from the South Dakota School of Mines and Technology and a PhD in physics from the University of Hawaii.
Director of Engineering
Mr. Gupta has served as NeuroSigma’s Director of Engineering since April 2015. Prior to working with NeuroSigma, he founded SelfEx Solutions, a Nitinol medical device consultancy that provided engineering services to start-ups for the design and development of Nitinol-based medical devices. Specifically, he provided their engineering teams guidance on the selection of materials, the design and processing of Nitinol-based medical devices, and on prototyping and development of the fully-assembled system to complete all the testing through to pre-clinicals. Prior to this, he served as the Manager of Advanced Research and Development at Penumbra, Inc., a leading neurovascular device company. During his time at Penumbra, Mr. Gupta led the engineering effort for a number of neurovascular devices, including the Penumbra Stroke System and the Separator-3D stentriever device, both of which have received FDA approval. Prior to Penumbra, from 1997 to 2004, Mr. Gupta worked at TiNi Alloy Co. with Dr. David Johnson where he helped develop some of the techniques currently used by NeuroSigma to fabricate its Thin Film Nitinol technology. While at TiNi Alloy Co., he also collaborated with SMART Therapeutics, Inc. in the development of the first neurovascular stent, Neuroform, which is used for the treatment of the aneurysms in the brain.
Mr. Gupta has a BSc in Physics from the University of Rajasthan, India as well as Masters Degrees in Physics from the Indian Institute of Technology at Delhi, in Electronics from the Queen’s University in Belfast, Northern Ireland, and in Micro-Electro-Mechanical Systems (MEMS) from Simon Fraser University in British Columbia, Canada.
Mr. Miller has served as Clinical Research Administrator for clinical trials conducted at the University of California, Los Angeles exploring therapies for epilepsy and depression. He has worked closely with Drs. Christopher DeGiorgio and Ian Cook in the development of Trigeminal Nerve Stimulation (TNS) and, in collaboration with Dr. DeGiorgio, has helped develop new tools and biomarkers for determining the risk in Sudden Unexplained Death in Epilepsy (SUDEP).
Mr. Miller received a BS in Electrical Engineering from the University of California, Irvine and an MFA from the University of California, San Diego.